SG11202012124PA - Pharmaceutical composition comprising hyaluronic acid and stem cells for treating cartilage damage-associated disease - Google Patents

Pharmaceutical composition comprising hyaluronic acid and stem cells for treating cartilage damage-associated disease

Info

Publication number
SG11202012124PA
SG11202012124PA SG11202012124PA SG11202012124PA SG11202012124PA SG 11202012124P A SG11202012124P A SG 11202012124PA SG 11202012124P A SG11202012124P A SG 11202012124PA SG 11202012124P A SG11202012124P A SG 11202012124PA SG 11202012124P A SG11202012124P A SG 11202012124PA
Authority
SG
Singapore
Prior art keywords
pharmaceutical composition
stem cells
hyaluronic acid
associated disease
cartilage damage
Prior art date
Application number
SG11202012124PA
Other languages
English (en)
Inventor
yun sun Yang
Wonil Oh
Soo Jin Choi
Miyoung Lee
Jueun Ha
Minju Lee
Original Assignee
Medipost Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medipost Co Ltd filed Critical Medipost Co Ltd
Publication of SG11202012124PA publication Critical patent/SG11202012124PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
SG11202012124PA 2018-06-05 2019-06-05 Pharmaceutical composition comprising hyaluronic acid and stem cells for treating cartilage damage-associated disease SG11202012124PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862680748P 2018-06-05 2018-06-05
PCT/KR2019/006816 WO2019235853A1 (fr) 2018-06-05 2019-06-05 Composition pharmaceutique comprenant de l'acide hyaluronique et des cellules souches permettant de traiter une maladie associée à des lésions du cartilage

Publications (1)

Publication Number Publication Date
SG11202012124PA true SG11202012124PA (en) 2021-01-28

Family

ID=68769796

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11202012124PA SG11202012124PA (en) 2018-06-05 2019-06-05 Pharmaceutical composition comprising hyaluronic acid and stem cells for treating cartilage damage-associated disease
SG11202011927TA SG11202011927TA (en) 2018-06-05 2019-06-05 Pharmaceutical composition comprising mesenchymal stem cells as effective ingredient for prevention or treatment of inflammatory disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11202011927TA SG11202011927TA (en) 2018-06-05 2019-06-05 Pharmaceutical composition comprising mesenchymal stem cells as effective ingredient for prevention or treatment of inflammatory disease

Country Status (9)

Country Link
US (2) US20210228637A1 (fr)
EP (2) EP3804736A4 (fr)
JP (2) JP7343091B2 (fr)
KR (2) KR20210008873A (fr)
CN (2) CN112261943A (fr)
AU (2) AU2019283518A1 (fr)
CA (2) CA3100471A1 (fr)
SG (2) SG11202012124PA (fr)
WO (2) WO2019235854A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220152137A (ko) 2021-05-07 2022-11-15 의료법인 성광의료재단 골 분화능 기능강화 중간엽 줄기세포 및 이의 용도
CN113616675A (zh) * 2021-08-23 2021-11-09 上海太安堂生物医学有限公司 含间充质干细胞的组合物及其在治疗退行性关节炎的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1272022C (zh) * 2001-08-14 2006-08-30 美迪宝斯特有限公司 用于治疗关节软骨损伤的组合物
JP2007535486A (ja) * 2003-05-07 2007-12-06 ラ ホーヤ インスティチュート フォー モレキュラー メディシン 高分子量のヒアルロン酸を用いた内因性又は埋め込まれた又は移植された幹細胞の機能回復を促進するための方法
EP3461884A1 (fr) * 2004-03-22 2019-04-03 Mesoblast International Sàrl Cellules souches mésenchymateuses et utilisations associées
AU2005228778B2 (en) 2004-03-31 2010-04-01 Yukio Kato Therapeutic agents and therapeutic methods for treating injured tissue
JP2009518132A (ja) * 2005-12-07 2009-05-07 イスト・テクノロジーズ・インコーポレイテッド 軟骨修復方法
US20070178073A1 (en) * 2006-02-01 2007-08-02 Samsung Life Public Welfare Foundation Composition Comprising Separated or Proliferated Cells from Umbilical Cord Blood for Treating Developmental and/or Chronic Lung Disease
SI2120977T1 (sl) * 2007-02-12 2014-01-31 Anthrogenesis Coroporation Zdravljenje vnetnih bolezni z uporabo placentarnih matičnih celic
WO2008144820A1 (fr) * 2007-05-28 2008-12-04 Monash University Traitement d'une maladie chronique des poumons
EP2257289B1 (fr) * 2008-02-15 2018-09-19 Bone Therapeutics Composition pharmaceutique pour le traitement ou la prévention de maladies ostéo-articulaires
CN103263440A (zh) * 2013-02-08 2013-08-28 周胜利 从胎盘、脐带中提、制同源性间充质干细胞注射剂的方法
WO2015022670A1 (fr) 2013-08-14 2015-02-19 Stempeutics Research Pvt. Ltd. Traitement de l'arthrose au moyen de cellules souches mésenchymateuses allogéniques groupées
JP6173157B2 (ja) * 2013-10-02 2017-08-02 日本製薬株式会社 Ｉｌ−１７産生抑制組成物
US20170166869A1 (en) * 2014-02-04 2017-06-15 Jose Javier Lopez GONZALEZ Biologically optimized adult mesenchymal stem cells
GB201410504D0 (en) * 2014-06-12 2014-07-30 Cell Therapy Ltd Immuno-modulaltory progenitor (IMP) cell
CN106573017B (zh) * 2014-06-30 2021-06-11 泰根尼克斯独资有限公司 用于治疗脓毒症的间充质基质细胞
KR101779763B1 (ko) * 2015-03-04 2017-09-19 메디포스트(주) 증식력 및 분화능이 개선된 간엽줄기세포를 포함하는 폐질환 예방 또는 치료용 약학적 조성물
JP6811724B2 (ja) * 2015-04-24 2021-01-13 ティジェニクス エス．エー．ユー． 細胞療法に対する臨床応答を決定するためのバイオマーカー
CN104840486A (zh) * 2015-04-30 2015-08-19 北京益诺勤生物技术有限公司 一种组合物及其应用、制剂
HUP1500218A2 (hu) * 2015-05-08 2016-11-28 Deltabio 2000 Kft Eljárás és készítmény ortopédiai betegségek, így ízületiporc-sérülések, különösen ízületi diszplázia kezelésére
EP3097922A1 (fr) 2015-05-28 2016-11-30 Denis Barritault Composition pour le traitement des lesions tissulaires
WO2017147649A1 (fr) 2016-02-29 2017-09-08 Magellan Stem Cells Pty Ltd Méthodes de traitement
CN105796600B (zh) * 2016-04-28 2020-02-28 博雅干细胞科技有限公司 使用干细胞治疗骨关节炎的方法和组合物
US20180021380A1 (en) * 2016-07-21 2018-01-25 Sungkwang Medical Foundation Composition including mesenchymal stem cell derived from adipose tissues and hyaluronic acid derivative, method of preparing the same, and method of preventing or treating low back pain using the same
WO2018080990A1 (fr) * 2016-10-24 2018-05-03 United Therapeutics Corporation Amélioration de propriétés immunomodulatrices des csm par le tréprostinil
AU2017354272A1 (en) * 2016-11-03 2019-05-23 Exostem Biotec Ltd. Mesenchymal stem cells populations, their products, and use thereof
CN111518758A (zh) * 2020-04-30 2020-08-11 深圳市合一康生物科技股份有限公司 一种用于肺病治疗的脐带间充质干细胞及其制备方法
CN113018317A (zh) * 2021-02-03 2021-06-25 上海兰天生物医药科技有限公司 间充质干细胞联合玻璃酸钠在治疗关节炎中的应用

Also Published As

Publication number Publication date
SG11202011927TA (en) 2020-12-30
CN112261944A (zh) 2021-01-22
AU2019283517A1 (en) 2021-01-21
EP3804736A4 (fr) 2022-03-30
WO2019235853A1 (fr) 2019-12-12
KR20210008101A (ko) 2021-01-20
JP2021526135A (ja) 2021-09-30
EP3811951A4 (fr) 2022-07-13
CA3100471A1 (fr) 2019-12-12
JP7480454B2 (ja) 2024-05-10
WO2019235854A1 (fr) 2019-12-12
CN112261943A (zh) 2021-01-22
JP7343091B2 (ja) 2023-09-12
KR20210008873A (ko) 2021-01-25
EP3811951A1 (fr) 2021-04-28
US20210228637A1 (en) 2021-07-29
JP2021526137A (ja) 2021-09-30
US20210228636A1 (en) 2021-07-29
EP3804736A1 (fr) 2021-04-14
CA3100466A1 (fr) 2019-12-12
AU2019283518A1 (en) 2021-01-14

Similar Documents

Publication Publication Date Title
IL263174A (en) Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases
EP3458574A4 (fr) Cellule souche mésenchymateuse et son utilisation pour le traitement des lésions musculaires et des maladies associées aux muscles
RS60990B1 (sr) Postupak za lečenje tumora, farmaceutska kompozicija i kutija sa medicinskim kompletom
EP2658561A4 (fr) Composition pharmaceutique pour prévenir ou traiter des maladies inflammatoires comprenant un extrait de trachelospermi caulis et un extrait de paeonia suffruticosa andrews, et son procédé de préparation
PH12016502005A1 (en) Compounds and compositions for inducing chondrogenesis
ZA201403596B (en) Composition for use in the promotion of healthy bone growth and/or in the prevention and/or treatment of bone disease
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
MA39710A (fr) Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
EP3342858A4 (fr) Cellules souches mésenchymateuses positives à ror1 et leur procédé de préparation, composition pharmaceutique les contenant et son procédé de préparation, et méthode destinée à prévenir ou à traiter des maladies à l'aide desdites cellules souches mésenchymateuses positives à ror1
ZA202100703B (en) Compositions and methods for treating inflammasome related diseases or conditions
EP3403658C0 (fr) Composition pour le traitement des maladies neuro-inflammatoires contenant des cellules souches neurales ou leur sécrétome comme ingrédient actif
IL274578A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
EP3586853A4 (fr) Composition pharmaceutique comprenant cellule souche mésenchymateuse stimulée par l'inflammation pour la prévention ou le traitement d'une maladie immunitaire ou d'une maladie inflammatoire
PL3192512T3 (pl) Nowa kompozycja farmaceutyczna do zapobiegania i/albo leczenia nietrzymania moczu
SG11202012124PA (en) Pharmaceutical composition comprising hyaluronic acid and stem cells for treating cartilage damage-associated disease
EP4000609A4 (fr) Composition pharmaceutique pour prévenir ou traiter des maladies osseuses
EP3377622A4 (fr) Libération ciblée dans des types de cellules d'intérêt de protéines thérapeutiques bioencapsulées dans des cellules végétales pour le traitement de maladies
GB201503967D0 (en) Biocompatible implants for use in tendon therapy
IL272495A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
EP3235808A4 (fr) Taurine modifiée, et composition pharmaceutique destinée à prévenir ou à traiter des maladies métaboliques la contenant
IL283956A (en) Methods and preparations for the treatment of glycogen storage diseases
EP3903794A4 (fr) Composition pharmaceutique comprenant des cellules souches clonales pour le traitement la maladie du greffon contre l'hôte
EP3397267A4 (fr) Peptides pour le traitement d'une maladie à résorption osseuse
EP4003381A4 (fr) Compositions et méthodes de traitement d'infections cutanées et d'autres maladies
EP3500591A4 (fr) Compositions et méthodes destinées au traitement des maladies associées aux os